Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 2, 2015, Pages 224-231

  Kopecky, Chantal ^a   Genser, Bernd ^b,c,d   Drechsler, Christiane ^e   Krane, Vera ^e   Kaltenecker, Christopher C ^a   Hengstschl€Ager, Markus ^a   M€Arz, Winfried ^c,f,g   Wanner, Christoph ^e   S€Aemann, Marcus D ^a   Weichhart, Thomas ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b BGStats Consulting   (Austria)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g SYNLAB ACADEMY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SERUM AMYLOID A; SURFACTANT PROTEIN B; BIOLOGICAL MARKER; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART ARRHYTHMIA; HEART DEATH; HEART DISEASE; HEART INFARCTION; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SUDDEN CARDIAC DEATH; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GERMANY; HEART DISEASES; KIDNEY FAILURE, CHRONIC; MALE; METABOLISM; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; TIME FACTOR; TREATMENT OUTCOME;

AGED; ATORVASTATIN CALCIUM; BIOMARKERS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; FEMALE; GERMANY; HEART DISEASES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN B; PYRROLES; RENAL DIALYSIS; RISK FACTORS; SERUM AMYLOID A PROTEIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923766304     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.06560714     Document Type: Article

References (50)

1. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr., Bangdiwala S, Tyroler HA: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79: 8–15, 1989.
2. Rye KA, Barter PJ: Cardioprotective functions of HDLs. J Lipid Res 55: 168–179, 2014.
3. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM: HDL and cardiovascular disease: Atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 8: 222–232, 2011.
4. Säemann MD, Poglitsch M, Kopecky C, Haidinger M, Hörl WH, Weichhart T: The versatility of HDL: A crucial anti-inflammatory regulator. Eur J Clin Invest 40: 1131–1143, 2010.
5. Rosenson RS, Brewer HB Jr., Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L: Cholesterol efflux and atheroprotection: Advancing the concept of reverse cholesterol transport. Circulation 125: 1905–1919, 2012.
6. Schaefer EJ: Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: Why have they failed in lowering coronary heart disease risk? Curr Opin Lipidol 24: 259–264, 2013.
7. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357: 2109–2122, 2007.
8. Schwartz GG, Olsson AG, Barter PJ: Dalcetrapib in patients with an acute coronary syndrome. N Engl J Med 368: 869–870, 2013.
9. Mahdy Ali K, Wonnerth A, Huber K, Wojta J: Cardiovascular disease risk reduction by raising HDL cholesterol—current therapies and future opportunities. Br J Pharmacol 167: 1177–1194, 2012.
10. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ: Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364: 127–135, 2011.
11. Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, Wu P, Blechacz B, Bassler D, Wei X, Sharman A, Whitt I, Alves da Silva S, Khalid Z, Nordmann AJ, Zhou Q, Walter SD, Vale N, Bhatnagar N, O’Regan C, Mills EJ, Bucher HC, Montori VM, Guyatt GH: Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: Systematic review and meta-regression analysis. BMJ 338: b92, 2009.
12. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Hólm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart A, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML, Perola M, Havulinna A, de Faire U, Gigante B, Ingelsson E, Zeller T, Wild P, de Bakker PI, Klungel OH, Maitland-van der Zee AH, Peters BJ, de Boer A, Grobbee DE, Kamphuisen PW, Deneer VH, Elbers CC, Onland-Moret NC, Hofker MH, Wijmenga C, Verschuren WM, Boer JM, van der Schouw YT, Rasheed A, Frossard P, Demissie S, Willer C, Do R, Ordovas JM, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burtt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, König IR, Fischer M, Hengstenberg C, Ziegler A, Buysschaert I, Lambrechts D, Van deWerf F, Fox KA, El Mokhtari NE, Rubin D, Schrezenmeir J, Schreiber S, Schäfer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander O, Mannucci PM, Ardissino D, Siscovick D, Elosua R, Stefansson K, O’Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D, Kathiresan S: Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study. Lancet 380: 572–580, 2012.
13. van Capelleveen JC, Bochem AE, Motazacker MM, Hovingh GK, Kastelein JJ: Genetics of HDL-C: A causal link to atherosclerosis? Curr Atheroscler Rep 15: 326, 2013.
14. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy ST, Fogelman AM: Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than highdensity lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108: 2751–2756, 2003.
15. Ray K, Wainwright NW, Visser L, Witteman J, Breteler M, Ambegaonkar B, Hofman A, Stricker B, Wareham N, Khaw KT, Sandhu M: Changes in HDL cholesterol and cardiovascular outcomes after lipid modification therapy. Heart 98: 780–785, 2012.
16. Toth PP, Barter PJ, Rosenson RS, Boden WE, Chapman MJ, Cuchel M, D’Agostino RB Sr., Davidson MH, Davidson WS, Heinecke JW, Karas RH, Kontush A, Krauss RM, Miller M, Rader DJ: Highdensity lipoproteins: A consensus statement from the National Lipid Association. J Clin Lipidol 7: 484–525, 2013.
17. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, Matsushita K, Wen CP: Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention. Lancet 382: 339–352, 2013.
18. Vaziri ND, Navab M, Fogelman AM: HDL metabolismand activity in chronic kidney disease. Nat Rev Nephrol 6: 287–296, 2010.
19. Wang F, Zheng J, Ye P, Luo L, Bai Y, Xu R, Sheng L, Xiao T, Wu H: Association of high-density lipoprotein cholesterol with the estimated glomerular filtration rate in a community-based population. PLoS ONE 8: e79738, 2013.
20. Baragetti A, Norata GD, Sarcina C, Rastelli F, Grigore L, Garlaschelli K, Uboldi P, Baragetti I, Pozzi C, Catapano AL: High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease. J Intern Med 274: 252–262, 2013.
21. Shoji T, Masakane I, Watanabe Y, Iseki K, Tsubakihara Y; Committee of Renal Data Registry, Japanese Society for Dialysis Therapy: Elevated non-high-density lipoprotein cholesterol (non- HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol 6: 1112–1120, 2011.
22. Zewinger S, Speer T, Kleber ME, Scharnagl H, Woitas R, Lepper PM, Pfahler K, Seiler S, Heine GH, März W, Silbernagel G, Fliser D: HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction. J Am Soc Nephrol 25: 1073–1082, 2014.
23. Silbernagel G, Genser B, Drechsler C, Scharnagl H, Grammer TB, Stojakovic T, Krane V, Ritz E, Wanner C, März W: HDL cholesterol, apolipoproteins, and cardiovascular risk in hemodialysis patients [published online ahead of print July 10, 2014]. J AmSoc Nephrol doi:ASN.2013080816.
24. Kalantar-Zadeh K, Kopple JD, Kamranpour N, Fogelman AM, Navab M: HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int 72: 1149–1156, 2007.
25. Weichhart T, Kopecky C, Kubicek M, Haidinger M, Döller D, Katholnig K, Suarna C, Eller P, Tölle M, Gerner C, Zlabinger GJ, van der Giet M, Hörl WH, Stocker R, Säemann MD: Serum amyloid A in uremic HDL promotes inflammation. J AmSoc Nephrol 23: 934–947, 2012.
26. Holzer M, Birner-Gruenberger R, Stojakovic T, El-Gamal D, Binder V, Wadsack C, Heinemann A, Marsche G: Uremia alters HDL composition and function. J Am Soc Nephrol 22: 1631–1641, 2011.
27. Yamamoto S, Yancey PG, Ikizler TA, Jerome WG, Kaseda R, Cox B, Bian A, Shintani A, Fogo AB, Linton MF, Fazio S, Kon V: Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol 60: 2372–2379, 2012.
28. Rothblat GH, Phillips MC: High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol 21: 229–238, 2010.
29. Huang R, Silva RA, Jerome WG, Kontush A, Chapman MJ, Curtiss LK, Hodges TJ, Davidson WS: Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat Struct Mol Biol 18: 416–422, 2011.
30. Gordon S, Durairaj A, Lu JL, Davidson WS: High-density lipoprotein proteomics: Identifying new drug targets and biomarkers by understanding functionality. Curr Cardiovasc Risk Rep 4: 1–8, 2010.
31. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, Vuletic S, Kassim S, Singh P, Chea H, Knopp RH, Brunzell J, Geary R, Chait A, Zhao XQ, Elkon K, Marcovina S, Ridker P, Oram JF, Heinecke JW: Shotgun proteomics implicates protease inhibition and complement activation in the antiin- flammatory properties of HDL. J Clin Invest 117: 746–756, 2007.
32. Riwanto M, Rohrer L, Roschitzki B, Besler C, Mocharla P, Mueller M, Perisa D, Heinrich K, Altwegg L, von Eckardstein A, Lüscher TF, Landmesser U: Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: Role of high-density lipoproteinproteome remodeling. Circulation 127: 891–904, 2013.
33. Tölle M, Huang T, Schuchardt M, Jankowski V, Prüfer N, Jankowski J, Tietge UJ, Zidek W, van der Giet M: High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc Res 94: 154–162, 2012.
34. Watanabe J, Charles-Schoeman C, Miao Y, Elashoff D, Lee YY, Katselis G, Lee TD, Reddy ST: Proteomic profiling following immunoaffinity capture of high-density lipoprotein: Association of acute-phase proteins and complement factors with proin- flammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum 64: 1828–1837, 2012.
35. Alwaili K, Bailey D, Awan Z, Bailey SD, Ruel I, Hafiane A, Krimbou L, Laboissiere S, Genest J: The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochim Biophys Acta 1821: 405–415, 2012.
36. Wanner C, Krane V, März W, Olschewski M, Asmus HG, Krämer W, Kühn KW, Kütemeyer H, Mann JF, Ruf G, Ritz E;DeutscheDiabetes- Dialyse-Studie (4D) Study Group: Randomized controlled trial on the efficacy andsafety of atorvastatin inpatientswith type2 diabetes on hemodialysis (4D study): Demographic and baseline characteristics. Kidney Blood Press Res 27: 259–266, 2004.
37. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238–248, 2005.
38. Wanner C, Krane V, Ruf G, März W, Ritz E; Die Deutsche DiabetesDialyse Studie Investigators: Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Kidney Int Suppl 71: S222–S226, 1999.
39. März W, Genser B, Drechsler C, Krane V, Grammer TB, Ritz E, Stojakovic T, Scharnagl H, Winkler K, Holme I, Holdaas H, Wanner C; German Diabetes and Dialysis Study Investigators: Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol 6: 1316–1325, 2011.
40. Kwan BC, Kronenberg F, Beddhu S, Cheung AK: Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 18: 1246–1261, 2007.
41. Moradi H, Vaziri ND, Kashyap ML, Said HM, Kalantar-Zadeh K: Role of HDL dysfunction in end-stage renal disease: A doubleedged sword. J Ren Nutr 23: 203–206, 2013.
42. Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, Kopple JD, Kalantar-Zadeh K: Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 18: 293–303, 2007.
43. Chang YT, Wu JL, Hsu CC, Wang JD, Sung JM: Diabetes and endstage renal disease synergistically contribute to increased incidence of cardiovascular events: A nationwide follow-up study during 1998-2009. Diabetes Care 37: 277–285, 2014.
44. Jardine MJ, Hata J, Woodward M, Perkovic V, Ninomiya T, Arima H, Zoungas S, Cass A, Patel A, Marre M, Mancia G, Mogensen CE, Poulter N, Chalmers J; ADVANCE Collaborative Group: Prediction of kidney-related outcomes in patients with type 2 diabetes. Am J Kidney Dis 60: 770–778, 2012.
45. Shah AS, Tan L, Long JL, Davidson WS: Proteomic diversity of high density lipoproteins:Our emerging understanding of its importance in lipid transport and beyond. J Lipid Res 54: 2575–2585, 2013.
46. Whitehead AS, de Beer MC, Steel DM, Rits M, Lelias JM, Lane WS, de Beer FC: Identification of novel members of the serum amyloid A protein superfamily as constitutive apolipoproteins of high density lipoprotein. J Biol Chem 267: 3862–3867, 1992.
47. Doyle IR, Bersten AD, Nicholas TE: Surfactant proteins-A and -B are elevated in plasma of patients with acute respiratory failure. Am J Respir Crit Care Med 156: 1217–1229, 1997.
48. Nguyen AB, Rohatgi A, Garcia CK, Ayers CR, Das SR, Lakoski SG, Berry JD, Khera A, McGuire DK, de Lemos JA: Interactions between smoking, pulmonary surfactant protein B, and atherosclerosis in the general population: The Dallas Heart Study. Arterioscler Thromb Vasc Biol 31: 2136–2143, 2011.
49. Rosenson RS, Brewer HB Jr., Ansell B, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, Webb NR: Translation of highdensity lipoprotein function into clinical practice: Current prospects and future challenges. Circulation 128: 1256–1267, 2013.
50. Mora S, Glynn RJ, Ridker PM: High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation 128: 1189–1197, 2013.